Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT05357612
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • Pimavanserin — DRUG
    PD related Psychosis

Study Details

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

Key Dates

Start date
Jan 23, 2023
Status verified
Aug 2025
Primary completion
Jun 30, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Pimavanserin

Primary Outcome Measure

Change in 5HT2A receptor density measured using the PET radioligand MH.MZ [ Time Frame: Baseline and 6 weeks after intervention of Pimavanserin ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical CenterNashvilleTennessee37212
Levi Pettit, BA
[email protected]
615-421-0569
Katie Hay, MS
[email protected]
6158757403

Find similar trials in Nashville, TN

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Vanderbilt University Medical Center· Nashville, TN

Related Studies